TNFSF10 and cancer: In fact, we have produced scFv-TRAIL fusion proteins in mammalian cells employing two different antibody fragments with one drug being constitutively active (regardless of the presence of a secondary cancer antigen), while the other drug was only active in the presence of the target antigen (D. Spitzer, unpublished data).